5374426 Rotavirus nucleocapsid protein VP6 in vaccine compositions

5374426 Rotavirus nucleocapsid protein VP6 in vaccine compositions

PATENT ABSTRACTS 804 A multivalent FeLV-infected feline vaccine composed of (1) a small but immunologically effective amount of inactivated feline l...

60KB Sizes 0 Downloads 0 Views

PATENT ABSTRACTS

804

A multivalent FeLV-infected feline vaccine composed of (1) a small but immunologically effective amount of inactivated feline leukemia virus; (2) a small but effective amount of an inactivated virus selected from the group consisting of Feline Rhinotracbeitis Virus, Feline Calici Virus and Feline Panleukopenia Virus; and (3) a pharmaceutically acceptable immunologica adjuvant. Components (1) and (2) may be inactivated by any of the known techniques. The inactivated feline leukemia virus must be from subgroup A and is the Rickard isolate of the virus designated FeLV-AR1. This combination vaccine is effective in preventing Viremia, leukemiaassociated syndromes, and deaths in cats caused by Feline Leukemia Virus, Feline Rhinotracheitis Virus, Feline Calici Virus and Feline Panleukemia Virus infections. 5374426 ROTAVIRUS NUCLEOCAPSID PROTEIN VP6 IN VACCINE COMPOSITIONS Sabara Marta; Frenchick Patrick J; Mullin-Reedy Kerry F Saskatoon, CANADA Assigned to University of Snskatehewan Immunological carrier complexes are provided utilizing the VP6 polypeptide from rotavirus as the carrier molecule. Also provided are methods of binding epitope-bearing molecules (e.g., hapteus) to the VP6 carrier molecule through binding peptides. The VP6 carrier can be a VP6 monomer, oligomer, or a particle.

5374431

helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interclmin crosslinking within and between the superhelical structures.

5374518 MONOCLONAL ANTIBODY FOR DIFFERENTIATING HIV-2 FROM HIM-1 SEROPOSITIVE INDIVIDUALS Hunt Jeffrey C; Satin Virender; Devare Sushil; Tribby Ilse I; Desai Suresh M; Casey James M Lindenhurst, IL, UNITED STATES Assigned to Abbott Laboratories A mouse monoclonal antibody is provided which detects HIV-2 seropositive individuals and differentiates them from HIV-1 seropositive individuals. The monoclonal antibody is specific for an epitope of HIV-2 gp41 which lies outside the characterized immunodominant region. The epitope recognized by the monocional antibody has the amino acid sequence HTTVPW.

5374549 PROCESS OF ENRICHING ADHERENT CD4+ T CELLS FROM MONOCYTE DEPLETED PERIPHERAL BLOOD MONONUCLEAR CELLS WITH INTERLEUKIN 2 AND INTERLEUKIN 4

SYNTHETIC BIOADHESIVE Pang Roy H; Cohen Charles M; Keck Peter C Medway, MA, UNITED STATES Assigned to Creative Biomolecules Inc This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an alpha-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the

Leung Kam H Brookhaven, PA, UNITED STATES Assigned to Terumo Corporation Peripheral blood monouuclear cells (PBMC) are treated to deplete monocytes and the remaining cells are cultured in a medium containing interleukin-2 0L-2) and interleukin-4 (IL-4). Nouadhereut cells are removed and discarded, and adherent cells are further cultured in a medium of IL-2 and IL-4 which expands the CD4+ T cells population of the PBMC. The expanded, enriched CD4+T cells can be placed in a pharmaceutically acceptable carrier and administered to a mammal with IL-2 to treat a tumor.